Prevalence of Diabetes in HIV Infected Patients and HIV Patients receiving Anti Retroviral Therapy: Cross Sectional study by Selvaraju, S
PREVALENCE OF DIABETES IN HIV INFECTED 
PATIENTS AND HIV PATIENTS RECEIVING ANTI 
RETROVIRAL THERAPY . 
                                                         - CROSS SECTIONAL STUDY. 
 
 
 
 
 
 
 
Dissertation submitted for 
 
MD Degree (Branch I) General Medicine 
March 2008 
                                                   
 
 
 
 
 
 
 
 
The Tamil Nadu Dr.M.G.R.Medical University 
Chennai, Tamil Nadu. 
 CERTIFICATE 
       This is to certify that this dissertation “PREVALENCE OF DIABETES  
 
IN HIV INFECTED PATIENTS AND HIV PATIENTS RECEIVING  
 
ANTI RETROVIRAL THERAPY” -CROSS SECTIONAL STUDY submitted 
by DR. S.SELVARAJU to the faculty of General Medicine, The Tamil Nadu  
Dr. M.G.R. Medical University, Chennai in partial fulfilment of the requirement 
for the award of MD degree Branch I (General Medicine) is a bonafide research 
work carried out by him under our direct supervision and guidance.  
 
 
 
 
 
 
 
 
 
 
Dr P. Selvaraj MD,      Dr. Ayyappan MD, 
Professor of Medicine ,     Professor and Head, 
Chief II Medical unit ,     Department of Medicine, 
Department of Medicine ,     Madurai Medical College, 
Madurai Medical College,     Madurai. 
Madurai. 
 
 
 
DECLARATION 
 
  
 I, Dr.S.Selvaraju solemnly declare that the dissertation titled 
“PREVALENCE OF DIABETES IN HIV INFECTED PATIENTS AND HIV 
PATIENTS RECEIVING ANTIRETROVIRAL THERAPY”-CROSS 
SECTIONAL STUDY has been prepared by me.  
 
 This is submitted to the Tamil Nadu, Dr. M.G.R. Medical University 
Chennai, in partial fulfilment of the regulations for the award of MD degree 
Branch I (General Medicine). 
 
 
 
 
Place : Madurai  
Date :        Dr. S.SELVARAJU 
 
 
 
 
 
                                         ACKNOWLEDGEMENT 
I express my sincere thanks to Dean, Govt Rajaji Hospital and Madurai 
Medical College for permitting me to use the facilities of Madurai Medical 
College and Govt. Rajaji Hospital to conduct this study.  
 
I will ever remain in gratitude to my chief Dr. P. Selvaraj M.D., Prof of 
Medicine, not only for guiding me through the study, but also for being my mentor 
and source of inspiration during the period of my post graduate training. 
 
I express my sincere thanks to Our professor and Head of the Department 
of Medicine Prof  Dr. A. Ayyappan and my beloved teachers Dr.M. Kamaraj 
MD., Dr.Moses K Daniel MD.,  Dr.S.Vadivel Murugan MD., 
Dr.D.Venkatraman MD., Dr.M.Muthiah MD.. 
 
I express my sincere thanks to our former Head of the Dept. of Medicine, 
Prof Dr. P.Thirumalaikolundu Subramanian MD for his guidance and valuable 
advice to conduct this study successfully. 
 
I express my sincere thanks to Professor of diabetology , Prof Dr. 
J.Asirvatham MD for his guidance and valuable advice. 
 
I express my heart felt thanks to my Assistant professors Dr. M. Natarajan 
MD., Dr.P.Purushothaman MD., Dr.R.Prabaharan MD.,for their valuable 
support and guidance through out my study.    
 
            I express my sincere thanks to Medical Officer in Anti Retroviral Therapy 
Centre Dr.S. Parthasarathy, and also staffs in the ART centre S.Prabhu, V.Raja 
mahendravarman, P.Mani, P.Aruna, M.Umadevi, R.Kayalvizhi, M.Ayyappan 
for their valuable support through out my study.    
 
             My family and friends have stood by me during my times of need. Their 
help and support have been valuable to the study.  
 
I would grossly fail in my duty if I fail to mention here of my patients who 
have ungrudgingly borne the pain and discomfort of investigations. I cannot but 
pray for their speedy recovery and place this study as a tribute to them and to the 
numerous others likely affected.  
 
 
 
 
                                                         CONTENTS 
     
          PAGE NO 
1. INTRODUCTION           1 
2. REVIEW OF LITERATURE        3 
3. AIMS AND OBJECTIVES        36   
4. MATERIALS AND METHODS      37 
5. RESULTS AND OBSERVATIONS               40 
6. DISCUSSION AND COMPARATIVE ANALYSIS   50 
7. SUMMARY                              57 
8. CONCLUSION        59 
 
APPENDIX  
1. BIBLIOGRAPHY  
2. GLOSSARY  
3. PROFORMA 
4. MASTER CHART 
 
 
 
 
                                         INTRODUCTION  
    
        
Many non-communicable diseases are set to increase dramatically during 
the 21st century. In particular, the prevalence of diabetes mellitus may double 
from 124 millions people worldwide in 1997 to 220 millions by 2010. More than 
97% of these patients will have type II diabetes. The projected increase in the 
number of diabetic patients will strain the capabilities of healthcare providers the 
world over. Thus it is of paramount importance to revisit the causes and 
epidemiology of diabetes mellitus. Ref 1 
Diabetes mellitus is caused by both environmental and genetic factors.   The 
environmental factors that may lead to the development of diabetes mellitus 
include physical inactivity, drugs and toxic agents, obesity, viral infection, and 
location. While type I diabetes is not a genetically predestined disease, an 
increased susceptibility can be inherited. Genetic susceptibility plays a crucial role 
in the etiology and manifestation of type II diabetes, with concordance in 
monozygotic twins approaching 100%. Genetic factors may have to be modified 
by environmental factors for diabetes mellitus to become overt. An individual with 
a susceptible gene may become diabetic if environmental factors modify the 
expression of these genes . 
Diabetes is a disease where the body does not produce enough, or dose not 
respond to the hormone insulin. This affects the regulation of the amount of 
glucose in the blood . Abnormalities in glucose metabolism (insulin resistance, 
hyperglycaemia, and diabetes mellitus) are a concern because persistently high 
blood glucose is associated with an increased risk of cardiovascular , renal  
diseases. The worldwide prevalence of DM has risen dramatically over the past 
two decades. With the greatest potential increases are Asia and Africa precisely 
the areas with the greatest potential increases in the prevalence of HIV infection 
and AIDS . Likewise, prevalence rates of IFG are also increasing. Although the 
prevalence of both type 1 and type 2 DM is increasing worldwide, the prevalence 
of type 2 DM is expected to rise more rapidly in the future because of increasing 
obesity and reduced activity levels. DM increases with aging. Type 2 DM is 
preceded by a period of IGT2, and a number of life-style modifications and 
pharmacologic agents prevent or delay the onset of DM. 
The Diabetes Prevention Program (DPP) demonstrated that intensive 
changes in life-style (diet and exercise for 30 min/day five times/week) in 
individuals with IGT prevented or delayed the development of type 2 diabetes by 
58% compared to placebo. This effect was seen in individuals regardless of age, 
sex, or ethnic group. In the same study, metformin prevented or delayed diabetes 
by 31% compared to placebo. For the prevention of diabetes we need to address 
the risk factors associated with the development of diabetes mellitus.  
                                                                                                                [ Ref23] 
 
 
Hyperinsulinemia and insulin resistance may be an intrinsic component of 
many disorders, such as hypertension, hyperlipidemia, and atherosclerosis. 
Medications that   also alter the glucose insulin homeostasis include Thiazide 
Diuretics , Beta-Blockers , Calcium-Channel Blockers , Corticosteroids and so on. 
Numerous studies have associated the HIV infection and the Anti retroviral 
agents with various metabolic complications, including diabetes. . More effective 
treatment in recent years has greatly increased the life span of people with 
HIV/AIDS. As patients live longer, we are placing more emphasis on enhancing 
the quality of their lives by treating HIV/AIDS as a long-term chronic condition . 
In considering these facts a study was conducted in Govt Rajaji Hospital , 
Madurai to estimate the prevalence of diabetes in HIV patients and those receiving 
Anti Retroviral Therapy. 
                                                  
 
 
 
 
                                 
  
 
 
 
 
 
 
 
                              REVIEW OF LITERATURE 
 
 
HISTORICAL ASPECTS 
 
                 The best early evidence of a description of the symptoms  
of diabetes in the world's literature is recorded in the Ebers papyrus   
that appears to date from 1550 B.C. This links the description of 
polyuria to Imhotep, a man of medicine, architecture, and magic, who 
was a high priest and minister to the Pharaoh Zosser in 3000 B.C. 
              The following masterly description of severe diabetes  
by Arateus from about A.D. 150 represents the sum of our knowledge 
up until the second half of the 17th century.[ref 17] 
              Diabetes is a wonderful affection, not very frequent 
amongmen, being a melting down of the flesh and limbs into urine. Its 
course is of a cold and humid nature, as in dropsy. The course is the 
common one, namely, the kidneys and the bladder; for the patients 
never stop making water, but the flow is incessant, as if from the 
opening of aqueducts. The nature of the disease then, is chronic, and 
it takes a long period to form: but the patient is short-lived, if the 
constitution of the disease be completely established; for the melting 
is rapid, the death speedy. 
            In 1674, Thomas Willis, a physician, an anatomist discovered  
 
(by tasting) that the urine of individuals with diabetes was sweet. It  
 
was Matthew Dobson of Manchester, England, who demonstrated, in  
 
1776, that persons with diabetes actually excrete sugar in the urine.  
 
After boiling urine to dryness, he noted that the residue, a crystalline  
 
material, had the appearance and taste of “brown sugar” .[ref 17] 
 
             Banting, Best, Collip, and Macleod demonstrated the new 
extract corrected the metabolic acidosis in the first person to receive 
the substance in January 1922 called insulin.  
 
 
 
EPIDEMIOLOGY         
 
 
 
 
                                                            [Ref16] 
 
 
[ ref 5 ] 
 
              
Diabetes mellitus is one of the most common endocrine disorders affecting 
almost 6% of the world's population. The number of diabetic patients will reach 
300 millions in 2025 (International Diabetes Federation, 2001). More than 97% of 
these patients will have type II diabetes. The projected increase in the number of 
diabetic patients will strain the capabilities of healthcare providers the world over. 
Thus it is of paramount importance to revisit the causes and epidemiology of 
diabetes mellitus. Diabetes mellitus is caused by both environmental and genetic 
factors. 
The incidence of type I diabetes ranged from 1.9 to 7.0/100,000/yr in 
Africa, 0.13 to 10/100,000/yr in Asia, 4.4/100,000/yr in Australasia, 3.4 to 
36/100,000/yr in Europe, 2.62 to 20.18/100,000/yr in the Middle East, 7.61 to 
25.7/100,000/yr in North America, and 1.27 to 18/100,000/yr in South America. 
The epidemiology of type II diabetes is equally bleak. The prevalence of type II 
diabetes ranged from 0.3 to 17.9% in Africa, 1.2 to 14.6% in Asia, 0.7 to 11.6% in 
Europe, 4.6 to 40% in the Middle East, 6.69 to 28.2% in North America, and 2.01 
to 17.4% in South America. [ ref 1 ]  
The prevalence of type 2 DM and its harbinger, IGT2, is highest 
in certain Pacific islands, intermediate in countries such as India and 
the United States, and relatively low in Russia and China. This 
variability is likely due to genetic, behavioral, and environmental 
factors. 
 
 
 
Evolution of the diabetes epidemic in India [ref 12] 
 
 
 
                   Estimated number of diabetic subjects in India. 
 
 The National Urban Diabetes Survey (NUDS), a population based study 
was conducted in six metropolitan cities across India and recruited 11,216 subjects 
aged 20 yr and above representative of all socio-economic strata.. The study 
reported that the age standardized prevalence of type 2 diabetes was 12.1 per cent. 
This study also revealed that the prevalence in the southern part of India to be 
higher-13.5 per cent in Chennai, 12.4 per cent in Bangalore, and 16.6 per cent in  
Hyderabad; compared to eastern India (Kolkatta) ,11.7 per cent; northern India 
(New Delhi), 11.6 per cent; and western India (Mumbai), 9.3 per cent. [ref12] 
The study also suggested that there was a large pool of subjects with 
impaired glucose tolerance (IGT), 14 per cent with a high risk of conversion to 
diabetes. [ref12] 
 
                                           Prevalance of Diabetes.  [ref 12,25,26,27,28,29.] 
DIAGNOSIS 
The Diabetes Expert Committee criteria  
  
 The Diabetes Expert Committee criteria  
  
  Normal Glucose 
Tolerance 
Impaired Glucose 
Tolerance 
Diabetes 
Mellitus2 
  
Fasting plasma glucose 
(mg/dL) 
          < 110         110–125   >/=   126  
Two hours after glucose 
load (mg/dL) 
 
          < 140 140–199 
  
     >/=200   
                                                                                             [ref 7]              
                                                                                
PATHOGENESIS;  
  
TYPE 1 DM 
              
Type 1 DM develops as a result of the synergistic effects of 
genetic, environmental, and immunologic factors that ultimately 
destroy the pancreatic beta cells. Features of diabetes do not become 
evident until a majority of beta cells are destroyed (~80%). At this 
point, residual functional beta cells still exist but are insufficient in  
number to maintain glucose tolerance. 
 
GENETIC CONSIDERATIONS 
The major susceptibility gene for type 1 DM is located in the 
HLA region on chromosome 6. Most individuals with type 1 DM have 
the HLA DR3 and/or DR4 haplotype. In addition to MHC class II 
associations, at least 17 different genetic loci contributes 
susceptibility to type 1DM. The risk of developing type 1 DM is 
increased tenfold in relatives of individuals with the disease 
 
AUTOIMMUNE FACTOR    
The following abnormalities in both the humoral and cellular 
arms of the immune system have identified. 
          (1) islet cell autoantibodies; 
          (2) activated lymphocytes in the islets, peripancreatic lymph 
nodes, and systemic circulation; 
           (3) T lymphocytes that proliferate when stimulated with islet 
proteins; and  
            (4) release of cytokines within the insulitis.                               
Pancreatic islet molecules targeted by the autoimmune process 
include insulin, glutamic acid decarboxylase (GAD, the biosynthetic 
enzyme for the neurotransmitter GABA), ICA-512/IA, and phogrin. 
Transplanted islets are destroyed by a recurrence of the autoimmune 
process of type 1A DM. .[ref3] 
 
ENVIRONMENTAL FACTORS 
Putative environmental triggers include viruses (coxsackie and 
rubella most prominently), bovine milk proteins, and nitrosourea 
compounds. .[ref3] 
 
TYPE 2 DM 
 
Insulin resistance and abnormal insulin secretion are central to 
the development of type 2 DM. Although controversy remains 
regarding the primary defect, most studies support the view that 
insulin resistance precedes insulin secretory defects and that diabetes 
develops only if insulin secretion becomes inadequate 
 
.  
GENETIC CONSIDERATIONS 
       Type 2 DM has a strong genetic component. Major genes that   predispose to 
this disorder have yet to be identified, but it is clear that the disease is polygenic 
and multifactorial. Various genetic loci contribute to susceptibility, and 
environmental factors (such as nutrition and physical activity) further modulate 
phenotypic expression of the disease. The concordance of type 2 DM in identical 
twins is between 70 and 90%. Individuals with a parent with type 2 DM have an 
increased risk of diabetes; if both parents have type 2 DM, the risk approaches 
40%. Insulin resistance, as demonstrated by reduced glucose utilization in skeletal 
muscle, is present in many nondiabetic, first-degree relatives of individuals with 
type 2 DM.[ref3] 
 
METABOLIC ABNORMALITIES; 
INSULIN RESISTANCE  
                       The decreased ability of insulin to act effectively on peripheral 
target tissues (especially muscle and liver) is a prominent feature of type 2 DM 
and results from a combination of genetic susceptibility and obesity. Insulin 
resistance is relative, however, since supernormal levels of circulating insulin will 
normalize the plasma glucose. 
Insulin resistance impairs glucose utilization by insulin-sensitive tissues 
and increases hepatic glucose output; both effects contribute to the hyperglycemia. 
Increased hepatic glucose output predominantly accounts for increased FPG14 
levels, whereas decreased peripheral glucose usage results in postprandial 
hyperglycemia .[ref3]                
The pathogenesis of insulin resistance is currently focused on a PI-3-kinase 
signaling defect, which reduces translocation of GLUT4 to the plasma membrane. 
OBESITY 
Obesity is generally associated with abdominal distribution of fat, 
producing an abnormally high waist-to-hip ratio. This "visceral" obesity, due to 
accumulation of fat in the omental and mesenteric regions, correlates with insulin 
resistance; subcutaneous abdominal fat seems to have less of an association with 
insulin insensitivity .Exercise may affect the deposition of visceral fat as suggested 
by CT scans of Japanese wrestlers, whose extreme obesity is predominantly 
subcutaneous. Their daily vigorous exercise program prevents accumulation of 
visceral fat, and they have normal serum lipids and euglycemia despite daily 
intakes of 5000–7000 kcal and development of massive subcutaneous obesity.  
Several adipokines, secreted by fat cells, can affect insulin action in  
obesity. Two of these, leptin and adiponectin, seem to increase sensitivity to 
insulin, presumably by increasing hepatic responsiveness. Two others tumor 
necrosis factor-which inactivates insulin receptors, and the newly discovered 
peptide resistin—interfere with insulin action on glucose metabolism and have 
been reported to be elevated in obese animal models. Mutations or abnormal levels 
of these adipokines may contribute to the development of insulin resistance in 
human obesity. [ref 4] 
IMPAIRED INSULIN SECRETION 
Insulin secretion initially increases in response to insulin resistance to 
maintain normal glucose tolerance. Initially, the insulin secretory defect is mild 
and selectively involves glucose-stimulated insulin secretion. The response to 
other nonglucose secretagogues, such as arginine, is preserved. Eventually, the 
insulin secretory defect progresses to a state of grossly inadequate insulin 
secretion. 
The reason(s) for the decline in insulin secretory capacity in type 2 DM is 
unclear. Islet amyloid polypeptide or amylin is cosecreted by the beta cell and 
likely forms the amyloid fibrillar deposit found in the islets of individuals with 
long-standing type 2 DM. Whether such islet amyloid deposits are a primary or 
secondary event is not known. The metabolic environment of diabetes may also 
negatively impact islet function. For example, chronic hyperglycemia 
paradoxically impairs islet function ("glucose toxicity") and leads to a worsening 
of hyperglycemia. Improvement in glycemic control is often associated with 
improved islet function. In addition, elevation of free fatty acid levels 
("lipotoxicity") and dietary fat may also worsen islet function. .[ref3] 
 
 
INCREASED HEPATIC GLUCOSE PRODUCTION 
In type 2 DM, insulin resistance in the liver reflects the failure of 
hyperinsulinemia to suppress gluconeogenesis, which results in fasting 
hyperglycemia and decreased glycogen storage by the liver in the postprandial 
state. Increased hepatic glucose production occurs early in the course of diabetes, 
though likely after the onset of insulin secretory abnormalities and insulin 
resistance in skeletal muscle. .[ref3] 
INSULIN RESISTANCE SYNDROMES  
The insulin resistance condition comprises a spectrum of disorders, with 
hyperglycemia representing one of the most readily diagnosed features. The 
metabolic syndrome, the insulin resistance syndrome, or syndrome X are terms 
used to describe a constellation of metabolic derangements that includes insulin 
resistance, hypertension, dyslipidemia [low high-density lipoprotein (HDL) and 
elevated triglycerides], central or visceral obesity, type 2 diabetes or IGT2/IFG 
and accelerated cardiovascular disease.[ref3]  
These associations have now been expanded to include small, dense, low-
density lipoprotein (LDL), hyperuricemia, , prothrombotic state with increased 
levels of plasminogen activator inhibitor type 1 (PAI-1), and proinflammatory 
state. 
 
 
 
OTHER SPECIFIC TYPES OF DIABETES MELLITUS 
 
MATURITY-ONSET DIABETES OF THE YOUNG (MODY)  
This subgroup is a relatively rare monogenic disorder characterized by 
non–insulin-dependent diabetes with autosomal dominant inheritance and an age 
at onset of 25 years or younger. Patients are nonobese, and their hyperglycemia is 
due to impaired glucose-induced secretion of insulin. Six types of MODY have 
been described. Except for MODY 2, in which a glucokinase gene is defective, all 
other types involve mutations of a nuclear transcription factor that regulates islet 
gene expression. 
MODY 2 is quite mild, associated with only slight fasting hyperglycemia 
and few if any microvascular diabetic complications. It generally responds well to 
hygienic measures or low doses of oral hypoglycemic agents. MODY 3—the most 
common form—accounts for two-thirds of all MODY cases. The clinical course is 
similar to that of idiopathic type 2 diabetes in terms of microangiopathy and 
failure to respond to oral agents with time. . [ref 4] 
 
 
 
 
 
 HYPERGLYCEMIA SECONDARY TO SPECIFIC CAUSES 
 
        
Hyperglycemia due to tissue insensitivity to insulin   
 Hormonal tumors (acromegaly, Cushing's syndrome, glucagonoma, 
pheochromocytoma) 
  
Pharmacologic agents (corticosteroids, sympathomimetic drugs, niacin)  
   
Liver disease (cirrhosis, hemochromatosis) 
  
 Muscle disorders (myotonic dystrophy) 
   
Adipose tissue disorders (lipodystrophy, truncal obesity) 
   
 Insulin receptor disorders (acanthosis nigricans syndromes, leprechaunism) 
 
Hyperglycemia due to reduced insulin secretion  
  
 Hormonal tumors (somatostatinoma, pheochromocytoma)  
  
 Pancreatic disorders (pancreatitis, hemosiderosis, hemochromatosis)  
   
Pharmacologic agents (thiazide diuretics, phenytoin, pentamidine)  
.                                                         
                                                                                                                                  [ref 4] 
 
 DRUG-INDUCED DISORDERS OF GLUCOSE TOLERANCE [ref 2] 
                      The association of medication with alterations in glucose-insulin 
homeostasis is not new. Polypharmacy enhances the risk for drug-drug interactions 
and adverse drug effects. 
  
[ref 2] 
                          
In patients with impaired glucose tolerance, medication can induce frank 
diabetes, which may manifest as hyperosmolar nonketotic coma. Discontinuation 
of diabetogenic medication may result in normal glucose tolerance with an 
improved quality of life for many patients. Furthermore, the reductions in plasma 
insulin levels and insulin resistance that often accompany improved glucose 
tolerance will retard the development of hyperlipidemia, coronary artery disease, 
and hypertension. It is particularly important to avoid combinations of drugs that 
may induce abnormalities in glucose insulin homeostasis. A commonly 
encountered example is the combination of ß-blockers and thiazides in 
hypertensive patients. [ref 2] 
In many cases, the mechanisms are not clearly recognized and need further  
evaluation. Recent evidence indicates that insulin pulsatility may be an important  
physiologic determinant of insulin action; however, few studies have examined the 
influence of pharmacologic agents on hormone pulsatility. Furthermore, it is 
probable that drugs may act at multiple sites to induce aberrations in glucose 
metabolism, as shownbelow. Medications such as ß-blockers may cause both 
hyper- and hypoglycemia. This apparent paradox may reflect factors such as dose, 
nutritional state, concomitant ingestion of other medication, severity of illness, 
patient age, and pancreatic islet cell reserve. The formulation of the medication 
(for example, sustained compared with regular release) should also be considered. 
Moreover, alcohol ingestion may influence.hepatic drug metabolism. In addition 
to its hypoglycemic effect, heavy alcohol use may result in glucose intolerance. It 
is prudent to monitor plasma glucose values when it is not possible to avoid 
medication with known effects on carbohydrate metabolism. [ref 2] 
                                                                                                       . [ref 2] 
CLINICAL FINDINGS 
                                                    
  Type 1 Diabetes Type 2 Diabetes 
Polyuria and thirst ++ + 
Weakness or fatigue ++ + 
Polyphagia with weight loss ++ – 
Recurrent blurred vision + ++ 
Vulvovaginitis or pruritus + ++ 
Peripheral neuropathy + ++ 
Nocturnal enuresis ++ – 
Often asymptomatic – ++  
 
While many patients with type 2 diabetes present with increased  urination 
and thirst, many others have an insidious onset of hyperglycemia and are 
asymptomatic initially. This is particularly true in obese patients, whose diabetes 
may be detected only after glycosuria or hyperglycemia is noted during routine 
laboratory studies. Occasionally, type 2 patients may present with evidence of 
neuropathic or cardiovascular complications because of occult disease present for 
some time prior to diagnosis. Chronic skin infections are common. Generalized 
pruritus and symptoms of vaginitis are frequently the initial complaints of women. 
Diabetes should be suspected in women with chronic candidal vulvovaginitis as 
well as in those who have delivered large babies (> 9 lb, or 4.1 kg) or have had 
polyhydramnios, preeclampsia, or unexplained fetal losses. . [ref 4] 
Obese diabetics may have any variety of fat distribution; however, diabetes 
seems to be more often associated in both men and women with localization of fat 
deposits on the upper segment of the body (particularly the abdomen, chest, neck, 
and face) and relatively less fat on the appendages, which may be quite muscular. 
Standardized tables of waist-to-hip ratio indicate that ratios of "greater than 0.9" in 
men and "greater than 0.8" in women are associatedwith an increased risk of 
diabetes in obese subjects. Mild hypertension is often present in obese diabetics. 
Eruptive xanthomas on the flexor surface of the limbs and on the buttocks and 
lipemia retinalis due to hyperchylomicronemia can occur in patients with 
uncontrolled type 2 diabetes who also have a familial form of 
hypertriglyceridemia. . [ref 4] 
HUMAN IMMUNODEFICIENCY VIRUS DISEASE 
INTRODUCTION 
AIDS was first recognized in 1981, when the unexplained occurrence of 
Pneumocystis carinii pneumonia in five previously healthy homosexual men in  
Los Angeles and of Kaposi's sarcoma (KS) in 26 previously healthy homosexual 
men in New York and Los Angeles. Within months, the disease became 
recognized in male and female injection drug users (IDUs) and soon thereafter in 
recipients of blood transfusions and in hemophiliacs. .[ref6] 
In 1983, human immunodeficiency virus (HIV) was isolated 
from a patient with lymphadenopathy, and by 1984 it was 
demonstrated clearly to be the causative agent of AIDS. In 1985, a 
sensitive enzyme-linked immunosorbent assay (ELISA) was 
Developed. .[ref6] 
 
DEFINITION 
Using the current CDC3 classification system , any HIV-
infected individual with a CD4+ T cell count of <200/uL has AIDS by 
definition, regardless of the presence of symptoms or opportunistic 
diseases.[ref6] 
EPIDEMIOLOGY 
 
                            HIV Incidence and Prevalence 2004 [ref 8] 
 
 
Region Living With HIV New Infections Adult Prevalence Deaths 
Sub-Saharan 25.4 million 3.1 million 7.4% 2.3 million
N. Africa, Middle East 540,000 92,000 0.3% 28,000 
South and Southeast Asia 7.1 million 890,000 0.6% 490,000 
East Asia 1.1 million 290,000 0.1% 51,000 
Latin America 1.7 million 240,000 0.6% 95,000 
Caribbean 440,000 53,000 2.3% 36,000 
East Europe 1.4 million 210,000 0.8% 60,000 
Western/Central Europe 610,000 21,000 0.3% 6500 
North America 1.0 million 44,000 0.6% 16,000 
Total 39.4 million 4.9 million 1.1% 3.1 million
 
 
[ref 9] 
 
 
HIV infection/AIDS is a global pandemic, with cases reported from 
virtually every country. The current estimate of the number of cases of HIV 
infection among adults worldwide is ~37 million, two-thirds of whom are in sub-
Saharan Africa; 50% of cases are women. In addition, an estimated 2.5 million 
children younger than age 15 are living with HIV/AIDS. [ref 6] 
 
                   
                                                                                                                                  
[ref 11] 
                                              A global view of HIV infection 
India has the largest number of people living with HIV outside South 
Africa—estimated at 4.6 million in 2002. Most infections are acquired sexually, 
but a small proportion is acquired through injecting drug use.  
In the southern states of Andhra Pradesh, Karnataka, Maharashtra, and 
Tamil Nadu, HIV is transmitted mainly through heterosexual sex, and is largely 
linked to sex work. Indeed, according to selected surveys, more than half of sex 
workers have become infected with HIV. 
  
[ref 9] 
 
In India, knowledge about HIV is still scant and incomplete. In a 2001 
national behavioural study of nearly 85000 people, only 75% of respondents had 
heard of AIDS and awareness was particularly low among rural women in Bihar, 
Gujarat and West Bengal. Less than 33% of all respondents had heard of sexually 
transmitted infections and only 21% were aware of the links between sexually 
transmitted infections and HIV. 
 
 
 
ETIOLOGIC AGENT  
• Gag Proteins and Precursor 
(p55) 
o Capsid Structural 
Protein (CA, p24)  
o Matrix Protein (MA, 
myristylated, p17)  
o RNA Binding Protein 
(p9)  
o RNA Binding Protein ( 
proline-rich, p7)  
o Other Gag Proteins( 
p6, p2, p1)  
• Viral Encoded Enzymes 
o Polymerase (p61,p55)  
 Reverse 
Transcriptase  
 Rnase H  
o Protease (p10)  
o Integrase (p32)  
• Envelope Proteins  
o Surface Glycoprotein 
(gp120)  
o Transmembrane 
Glycoprotein (gp41)  
• Accessory and Regulatory 
Proteins 
o Tat  
o Rev  
o Nef  
o Vif (Viral Infectivity 
Factor)  
o Vpr  
o Vpu  
o Vpx  
o Tev  
• Nucleic Acids 
o HIV RNA  
 
                                                                              [ref 13] 
The etiologic agent of AIDS is HIV, which belongs to the family of human 
retroviruses (Retroviridae) and the subfamily of lentiviruses.the HIV virion is an 
icosahedral structure containing numerous external spikes formed by the two 
major envelope proteins, the external gp120 and the transmembrane  gp41. 
 
TRANSMISSION 
[ref 12] 
 
HIV2 is transmitted by both homosexual and heterosexual contact; by 
blood and blood products; and by infected mothers to infants either intrapartum, 
perinatally, or via breast milk. 
 
PATHOPHYSIOLOGY AND PATHOGENESIS 
 
The hallmark of HIV disease is a profound immunodeficiency resulting 
primarily from a progressive quantitative and qualitative deficiency of the subset 
of T lymphocytes referred to as helper T cells 
When the number of CD4+ T cells declines below a certain 
level, the patient is at high risk of developing a variety of 
opportunistic diseases, particularly the infections and neoplasms that 
are AIDS-defining illnesses. Some features of AIDS, such as KS and 
neurologic abnormalities ,cannot be explained completely by the 
immunosuppressive effects of HIV, since these complications may 
occur prior to the development of severe immunologic impairment. 
[Ref6] 
The combination of viral pathogenic and immunopathogenic 
events that occurs during the course of HIV disease from the moment 
of initial (primary) infection through the development of advanced-
stage disease is complex and varied. It is important to appreciate that 
the pathogenic mechanisms of HIV disease are multifactorial and 
multiphasic [ref6] 
 
 
[ref14] 
ENDOCRINOLOGIC MANIFESTATIONS  
 
Hypogonadism is probably the most common endocrinologic abnormality 
in HIV-infected men.  
The adrenal gland is also a commonly afflicted endocrine gland in patients 
with AIDS. Abnormalities demonstrated on autopsy include infection (especially 
with CMV and M avium complex), infiltration with Kaposi's sarcoma, and injury 
from hemorrhage and presumed autoimmunity. The prevalence of clinically 
significant adrenal insufficiency is low. Patients with suggestive symptoms should 
undergo a cosyntropin stimulation test. [ ref7] 
Although frank deficiency of cortisol is rare, an isolated defect in 
mineralocorticoid metabolism may lead to salt-wasting and hyperkalemia.  
AIDS patients appear to have abnormalities of thyroid function tests 
different from those of patients with other chronic diseases. AIDS patients have 
been shown to have high levels of triiodothyronine (T3), thyroxine (T4), and 
thyroid-binding globulin and low levels of reverse triiodothyronine (rT3). The 
causes and clinical significance of these abnormalities are unknown. [ ref7] 
 
 
ANTIRETROVIRAL THERAPY 
 
The best time to initiate antiretroviral treatment remains controversial. It is 
best to weigh the benefits of viral suppression against the side effects of the drugs 
for each patient. In general, treatment for asymptomatic HIV disease should be 
initiated when the CD4 cell count drops below 350 cells/mcL or symptomatic HIV 
disease. Patients with rapidly dropping CD4 counts or very high viral loads 
(>100,000/mcL) should be considered for earlier treatment. For those patients who 
might have difficulty adhering to treatment or who are at higher risk for toxicity 
(eg, underlying liver disease), waiting until the CD4 count nears 200 cells/mcL 
may be a better strategy. 
. Antiretroviral therapy. 
  
Drug   Common Side Effects  
   
Zidovudine (AZT)   Anemia, neutropenia, nausea, malaise, headache, insomnia,  
myopathy  granulocytopenia , lactic acidosis , 
hepatomegaly with steatosis. 
Didanosine (ddI)   Peripheral neuropathy, pancreatitis, dry mouth, hepatitis, , 
abnormalities on liver function tests, lactic acidosis, 
hepatomegaly with steatosis. 
Zalcitabine (ddC)   Peripheral neuropathy, aphthous ulcers, hepatitis,  
pancreatitis, lactic acidosis, hepatomegaly with steatosis 
Stavudine (d4T))  Peripheral neuropathy, hepatitis, pancreatitis , lactic acidosis, 
hepatomegaly with steatosis, ascending neuromuscular 
weakness, lipodystrophy. 
Lamivudine (3TC)   Rash, peripheral neuropathy 
Emtricitabine   Skin discoloration palms/soles (mild) 
Abacavir   Rash, fever—if occur, rechallenge may be fatal 
   
Tenofovir   Gastrointestinal distress 
Saquinavir   Gastrointestinal distress 
Ritonavir   Gastrointestinal distress, peripheral paresthesias,                
 nausea, abdominal pain, hyperglycemia, fat  
redistribution, lipid abnormalities. 
Indinavir   Kidney stones, , hyperglycemia, fat redistribution, 
lipid abnormalities 
Nelfinavir   Diarrhea 
Amprenavir   Gastrointestinal, rash, nausea, vomiting, diarrhea, 
oral paresthesias, elevated liver function tests, 
hyperglycemia, fat redistribution, lipid abnormalities. 
Fosamprenavir   Same as amprenavir 
Lopinavir/ritonavir   Diarrhea 
Atazanavir   Hyperbilirubinemia, hyperglycemia, fat maldistribution 
Tipranavir/ritonavir   Gastrointestinal, rash 
   
Nevirapine)  Rash 
Delavirdine   Rash 
Efavirenz   Neurologic disturbances 
   
Enfuvirtide   Injection site pain and allergic reaction  
 
                                                                                                                      [ ref7] 
AIDS-related opportunistic infections and Treatment 
Treatment of AIDS-related opportunistic infections and malignancies. 
  
Infection or 
Malignancy 
Treatment Complications 
Trimethoprim-
sulfamethoxazole 
Nausea, neutropenia, anemia, 
hepatitis, drug rash, Stevens-
Johnson syndrome. 
Pentamidine Hypotension, hypoglycemia, 
anemia, neutropenia, pancreatitis, 
hepatitis. 
Trimethoprim, with 
dapsone,  
Nausea, rash, hemolytic anemia in 
G6PD3-deficient patients. 
Methemoglobinemia (weekly levels 
should be < 10% of total 
hemoglobin). 
  
Pneumocystis jiroveci 
infection 
  
Primaquine, and 
clindamycin,  
Hemolytic anemia in G6PD-
deficient patients. 
Methemoglobinemia, neutropenia, 
colitis.  
Atovaquone,  Rash, elevated aminotransferases, 
anemia, neutropenia. 
  
Clarithromycin,  Clarithromycin: hepatitis, nausea, 
diarrhea; ethambutol: hepatitis, 
optic neuritis.  
Mycobacterium 
avium complex 
infection  
Rifabutin,  Rash, hepatitis, uveitis. 
Toxoplasmosis Pyrimethamine combined 
with sulfadiazine,  
Leukopenia, rash.  
Lymphoma Combination chemotherapy 
(eg, modified CHOP, M-
BACOD, with or without 
G-CSF or GM-CSF).  
Nausea, vomiting, anemia, 
leukopenia, cardiac toxicity (with 
doxorubicin). 
Amphotericin B Fever, anemia, hypokalemia, 
azotemia.  
Cryptococcal 
meningitis 
Fluconazole,  Hepatitis. 
Valganciclovir,  Neutropenia, anemia, 
thrombocytopenia.  
Ganciclovir,  Neutropenia (especially when used 
concurrently with zidovudine), 
anemia, thrombocytopenia. 
Cytomegalovirus 
infection 
Foscarnet,  Nausea, hypokalemia, 
hypocalcemia, hyperphosphatemia, 
azotemia. 
Esophageal 
candidiasis or 
recurrent vaginal 
candidiasis 
Fluconazole,  Hepatitis, development of 
imidazole resistance.  
Acyclovir,  Resistant herpes simplex with 
chronic therapy.  
Valacyclovir,  Nausea. 
Herpes simplex 
infection 
Foscarnet See above. 
Kaposi's sarcoma      
  Limited cutaneous 
disease 
Observation, intralesional 
vinblastine. 
Inflammation, pain at site of 
injection.   
                         
Abnormalities in glucose metabolism have been described with increasing 
frequency in patients with HIV in many studies and may result from both direct 
and indirect effects of highly active antiretroviral therapies (HAART). 
Prevalence and Incidence of Pre-diabetes and Diabetes in the Multicenter 
AIDS Cohort Study showed HIV+ men with HAART exposure have an increased 
prevalence and incidence of pre-diabetes and DM. [ref 10] 
 
 
               
 
 
 
 
 
 
 
 
 
 
  AIMS AND OBJECTIVES 
 
 
1. To determine the prevalence of diabetes mellitus in HIV infected  
           Patients. 
  
2. To determine the prevalence of diabetes mellitus in HIV patients  
           receiving highly active anti retroviral therapy. 
 
 
 
 
                                        
 
 
                 
 
 
 
 
MATERIALS AND METHODS 
Setting  : All HIV patients who were attending anti retroviral therapy centre.  
 
GRH, Madurai.  
 
Collaborating Departments    :Anti retroviral therapy centre   
                                              Madurai Medical College 
       Madurai.  
       Department of Diabatology   
                                      Madurai Medical College  
       Madurai 
Design of the study     : cross sectional study 
Period of study      : 01.09.2006 – 31.10.2007 
Sample size         : 128 
Ethical committee approval  : Obtained  
Consent     : Informed consent was obtained  
Financial support     : Nil  
Conflict of interest    : Nil  
 
 
 
 
 
Selection and Details of Study subjects 
128 HIV patients who were attending Anti Retro Therapy Centre Govt 
Rajaji Hospital, during the period from 01.09.2006 – 31.10.2007 were included in 
the study.  
Inclusion criteria  
All HIV patients attending Anti Retro Therapy Centre were taken. 
Exclusion criteria  
1. Patients on medications other than ART [Beta-Blockers, 
ThiazideDiuretics, Corticosteroids, Phenytoin,OralContraceptives and Sex       
Hormones, Phenothiazines and all the drugs mentioned in (ref2) ] which are likely 
to produce glucose intolerance were excluded. 
            2. Conditions  that are likely to produce transient hyperglycemia like 
,patients with fever , Pneumonia, acutely ill patients were excluded. 
The total number of cases screened were 140. Of which 12 cases were 
excluded from the study. After exclusion of these patients, the total number of 
patients who were taken into account for our study was128.  
128 patients who were included in the study were divided into 5 groups 
1.Patients on D4T(30)+3TC+NVP were included in Group 1,  
2.Patients on D4T(30)+3TC+EFVwere included in Group2, 
  
3.Patients on ZDV+3TC+NVP were included in Group 3, 
  
4.Patients on ZDV+3TC+EFVwere included in Group 4,  
  
5.Patients not on any drugs were included in Group 5.  
 
The prevalence of DM was determined, defined as fasting glucose 
concentration of 126 mg/dL or more  or 2 hour post prandial glucose concentration 
of 200 mg/dL or higher on two subsequent days , self-reported DM, or self 
reported use of an anti diabetic medication (ie, insulin, sulfonylureas, 
thiazolidinediones, biguanides, meglitinides, or -glucosidase inhibitors). 
The prevalence of IGT AND IFG were also determined, 
           IFG - was defined as FPG >/= 110 mg/dL but < 126 mg/dL . 
           IGT - which was defined as plasma glucose levels between 7.8 and 11.1 
mmol/L (140 and 200 mg/dL) 2 hours after meal. [ref3] 
 
 
 
 
 
 
 
 
 
 
 
 
                         RESULTS AND OBSERVATIONS 
The collected data was analysed using Epidemiological information 
package 2002 developed by Centre for Disease Control (CDC) Atlanta in 
Collaboration with WHO. CHI square test was used for test of significance. These 
data was compared with published literature. 
 In our study, 128 HIV  patients were studied. 
A. CHARECTERISTICS OF CASES INCLUDED IN THE STUDY 
                              Table 1: Total cases 
 
Cases  
Group No. % 
1 50 39.1 
2 24 18.8 
3 18 14.1 
4 8 6.3 
5 28 21.9 
Total 128 100 
 
128 patients were included in the study and they were divided into 5 
groups. Patients on D4T(30)+3TC+NVP were included in Group 1( 50 ), Patients 
on D4T(30)+3TC+EFVwere included in Group2(24), Patients on 
ZDV+3TC+NVP were included in Group 3(18), Patients on ZDV+3TC+EFV 
were included in Group 4(8), Patients not on any drugs were included in Group 
5(28). 
                                           Table 2 :Age 
 
 
               Cases 
 
 
 
Age group in 
years  No. 
 
% 
< 10 3 2.3 
10-19 2 1.6 
20-29 34 26.6 
30-39 56 43.8 
40-49 26 20.3 
50 & Above 7 5.4 
Total 128 100 
Mean 
S.D. 
33.9 yrs 
9.2 yrs 
 
 
2.3% of patients belong to < 10 years of age, 1.6% of belong to 10 - 19 
years of age, 26.6%of patients belong to 20-29 years of age,  43.8 % of patients 
belong to 30-39 years of age, 26%of patients  belong to 40-49 years of age and 7% 
of patients  belong to 50 & Above years of age.  
                                                                     
 
 Table 3: sex 
 
 
                                                   
 
 
 
 
In our patients 60.2%were males and 39.8% were females. 
                                                               
                                                               Table 4: Marital status 
 
 
 
 
 
 
 
 
 
 
 
Among  128 study patients  82.8% were married and 17.2 were unmarried. 
                                                              
                                                
 
Cases 
Sex 
No. % 
Males 77 60.2 
Females 51 39.8 
Total 128 100 
Cases 
Marital status 
No. % 
Married 106 82.8 
Unmarried 22 17.2 
Total 128 100 
                                            Table 5: Marital status: BMI  
 
 
Parameter 
 
Mean 
 
S.D. 
Height 163.7 cms 11.9 cms 
Weight       56.6 kg.         8.5 kg 
B.M.I.        21.02         1.88 
 
 
In our patients mean height was 163.7 cms , mean weight was 56.6 kg and 
BMI was 21. 
 
B. RELATIONSHIP OF CHARACTERISTICS OF CASES AND  
     PREVALANCE OF D.M. & IGT/IFG 
                                    Table 6:  Age and Prevalance 
 
 
 
 
 
 
 
 
 
D.M. 
 
IGT/IFG 
 
Age in years 
Present Absent Present Absent
Mean 37.7 33.4 38.1 33.6 
S.D. 10.4 8.9 6 9.4 
’p’ 0.005 
Significant 
0.0474 
Significant 
  
In diabetes and IGT/IFG patients ,the mean age was 37.7 and 38.1 
respectively. Whereas in non glucose intolerance patients the mean agewas 33 
with  significant’ p’ value showed increased prevalence of glucose intolerance 
with increasing age. 
 
Table 7: Sex and Prevalance 
 
D.M. 
 
         IGT/IFG 
Present(17) Absent(111) Present(10) Absent(118)
 
Sex 
No. % No. % No. % No. % 
Males 11 64.7 66 59.5 6 60 71 60.2 
Females 6 35.3 45 40.5 4 40 47 39.8 
‘p’ 0.8843 
Not significant 
0.6199 
Not significant 
 
 
Out of 17 diabetic patients, males were 64.7% and females were 35.77%.In 
10  IGT/IFG patients males were 60% while females were 40% with insignificant 
‘p’ value showed the prevalence of glucose intolerance in our study was equal in 
both the sexes.  
                                               Table 8  : BMI and Prevalance 
 
 
D.M. 
 
IGT/IFG 
Present(17
) 
Absent(111) Present(10) Absent(118)
 
          B.M.I. 
No. % No. % No. % No. % 
Below normal  < 18.5 
Normal        18.5 – 24.9 
Overweight      > 24.9 
- 
17 
- 
- 
100 
- 
   12 
94 
5 
10.8 
84.7 
4.5 
    1 
9 
- 
 10 
90 
- 
 11 
102 
5 
  9.3 
86.4 
 4.2 
‘p’ 0.6786 
Not significant 
0.2967 
Not significant 
 
 
Among 128 patients 10.8% had BMI of < 18.5 , 84.7% had BMI of 18.5 – 
24.9 and 5% had BMI of > 24.9. All the 17 diabetic cases were within the range of 
18.5 – 24.9. In 10 IGT/IFG patients 90% were within the range of 18.5 – 24.9 and 
10% were  BMI of < 18.5, with insignificant ‘p’ value shows glucose intolerance 
in our study was not associated with high BMI value. 
 
 
 
 
 
 
Table 9:Prevalence of D.M./ IGT/IFG  
 
D.M. 
 
          IGT/IFG 
Present Absent Present Absent 
 
Group 
No. % No. % No. % No. % 
 
1(50) 
2 (24) 
3 (18) 
4 (8) 
5 (28) 
 
 
7 
4 
2 
1 
3 
 
14 
16.7 
11.1 
12.5 
10.7 
 
43 
20 
16 
7 
25 
 
86 
83.3 
88.9 
87.5 
89.3 
 
4 
2 
1 
1 
2 
 
8 
8.3 
5.6 
12.5
7.1 
 
46 
22 
17 
7 
26 
 
92 
91.7
94.4
87.5
92.9
Total ( 128) 17 13.3 111 86.7 10 7.8 118 92.2
 
 
The prevalence of diabetes mellitus was 13.3 % .In group 1 the prevalence 
was 14%.In group 2 it was16.7%.In group 3 it was 16%.In group 4 the prevalence 
was 12.5%. In group 5 it was 10.7%. The prevalence of IGT/IFG was 7.8% with 
8%, 8.3%, 5.6%, 12.5% 7.1% in group1,2,3,4&5 respectively. 
 
                                  
                                
 
   Prevalence of D.M & IGT/IFG 
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Table 10 :Prevalence of D.M./ IGT/IFG in HIV patients on HAART and Not 
on  HAART 
 
 
 
 Prevalence of D.M. in % 
Prevalence of IGT/IFG in % 
 
 
 
Group 
 
On 
HAART 
 
Not on 
HAART
Group 5
 
‘p’ 
 
 
On 
HAART 
 
 
Not on 
HAART 
 
‘p’ 
 
 1 14 
 
10.7   0.0249 
Significant  
 
8 7.1 0.4983 (Not 
Significant) 
2 16.7 10.7 0.0001 
Significant 
8.3 7.1 0.3562( Not 
Significant) 
3 11.1 10.7 0.4792 (Not 
Significant) 
5.6 7.1 0.1992 (Not 
significant ) 
 
4 12.5 10.7 0.2352 (Not 
Significant) 
12.5 7.1 0.0001 
Significant 
Total 14 10.7    0.0249 
 Significant 
8 7.1 0.4983  
Not Significant 
 
 
Prevalance of diabetes mellitus among HIV patients not receiving HAART 
[group 5] was 10.7% and prevalence among HIV patients on HAART was 
14%.There was increased prevalence of diabetes in patients on HAART than 
patients not on HAART with significant ‘p’ value. 
Considering individual groups , patients on Stavudine+Lamivudine 
+Nevirapine Group1& patients on Stavudine+Lamivudine +Efavirenzwere 
Group2, had higher prevalence with significant ‘p’ value. 
Prevalance of IGT/IFG among HIV patients not on HAART [group 5] was 
7.1% .Among patients on HAART it was 8% with insignificant ‘p’ value.                   
Considering individual groups Group 4 had higher prevalence with significant ‘p’ 
value. But the number of IGT/IFG patients in group 4 was only one made it 
insignificant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           DISCUSSION & COMPARATIVE ANALYSIS 
All the patients  who were attending anti retroviral therapy centre, GRH, 
Madurai were considered for the study.  patients on medications other than ART 
[Beta-Blockers, ThiazideDiuretics, Corticosteroids, Phenytoin,OralContraceptives 
and Sex Hormones, Phenothiazines and all the drugs mentioned in (ref2) ] and 
Conditions  that are likely to produce transient hyperglycemia like patients with 
fever , Pneumonia, acutely ill patients were excluded.. Finally 128 patients were 
selected and divided into 5 Groups based on treatment they have received. 
Patients on Stavudine+Lamivudine+Nevirapine were included in Group1, 
patients on Stavudine+Lamivudine +Efavirenz were included in Group2,Patients 
on Zidovudine+ Lamivudine +Nevirapine were included in Group 3, Patients on 
Zidovudine+ Lamivudine +Efavirenz were included in Group 4, and Patients not 
on any drugs were included in Group 5. 
Dose of drugs used in HAART was Stavudine 30mg, Lamivudine -150 mg , 
Nevirapine-200mg, Zidovudine-300mg and Efavirenz-600mg. 
Adherence to antiretroviral therapy was assessed by response to interviewer 
query, "On average, how often did you take your medication as prescribed?" All 
our patients were 100% adherent to HAART 
Urine analysis, Fasting blood sugar after atleast 8 hours fasting , Post 
prandial blood sugar 2 hours after meal , Blood urea, S.creatinine , CD4 count, 
liver function test, ECG were done for all the patients. 
Those patients with abnormal glucose value , the Fasting blood sugar and 
Post prandial blood sugar were repeated on the next day. 
BMI was calculated for all the patients using their height and weight. 
128 patients were included in our study and prevalence of diabetes and 
prediabetes were determined through cross sectional pattern. 
In our study the prevalence 0f diabetes was 13.3%. Many studies were 
conducted in india to determine the prevalence of diabetes in the general 
population.. In Raman kutty et al study the prevalence was 12.4 % in  
Thiruvananthapuram .In 2001 Misra et al study the prevalence was 10.3 in  New 
Delhi . In Mohan et al study the prevalence was  12 % in  Chennai. Another study 
in the same year was conducted by   Ramachandran  et al ,  National Urban 
diabetes Survey showed the pravalance of 12.1% . [ ref 11] .Compared to these 
studies which were conducted in the the general population the pravalance was 
higher in our study i.e, 13.3%which was conducted among HIV seropositive 
patients and those receiving antiretroviral therapy.                                                 
 
    
    
 
 
 
 
    Prevalance of diabetes in urban India [ ref 11,13,14,15,16,18,19,20,21] 
 
Year         Author                           Place                                         prevalance   (%) 
1972        Ahuja                        ICMR Multicentre Study                                 2.1 
1979        SR Iyer et al.             Bardoli                                                             4.4 
1988        Ramachandran         Kudremukh                                                        5.0 
1992        Ramchandran           Chennai                                                              8.2 
 
2000        Raman kutty             Thiruvananthapuram                                        12.4 
2001         Iyer                           Dombivli                                                           7.5 
2001         Misra                        New Delhi                                                        10.3 
2001         Mohan                     Chennai                                                             12.0 
2001         Ramachandran         National Urban diabetes Survey(Six Cities)    12.1 
2002          Gupta 17                                                               Jaipur                                                                 12.7 
 
Looking at the region-wise prevalance of diabetes, in a recent study 
conducted  among urban subjects [National Urban diabetes Survey(NUDS)] the 
prevalance of diabetes in the southern part of India was found to be higher -13.5% 
among Chennai residents, in Bangalore 12.4% and Hyderabad 16.6% than eastern 
India 11.7% (Kolkatta), northern India 11.6% (New Delhi) and western India 
9.3% (Mumbai).Thus it is clear that in the last two decades, there has been a 
marked increase in the prevalance of diabetes among urban Indians. 
                   
 
All the  diabetic cases in our study were within the range of BMI i.e., 18.5 –   
24.9. Majority of the diabetic subjects in India are LBW type 2 DM. There are 
several publications on this subject. The pathogenesis of this disorder is not clear 
 
Prediabetes- the harbinger of future diabetes 
 
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) 
collectively called as prediabetic states, have a high risk of conversion to diabetes. 
Several studies have shown that these prediabetic states are also high risk stages 
for cardiovascular disease. Hence data on IGT and IFG are also urgently needed as 
they are indicators of future diabetes prevalence and burden on the nation. 
The National Urban Diabetes Survey (NUDS) results indicate the 
prevalence of IGT was 16.8 per cent in Chennai, 14.9 per cent in Bengaluru 
(formerly Bangalore), 29.8 per cent in Hyderabad, 10 per cent in Kolkatta, 10.8 
per cent in Mumbai and 8.6 per cent in New Delhi. The ADEPS done in Kerala 
showed that 11.2 per cent of the subjects had either IFG or IGT. 
                            Prevalence of Impaired glucose tolerance at Chennai. 
 
A recent study has reported a decreased prevalence of IGT in an urban 
population compared to earlier studies done in Chennai (16.8% in 2000 to 10.2% 
in 2004). In our study also the prevalence of IFG/ IGT was 7.8% much lower than 
the general population. This could suggest that the diabetes epidemic in urban 
India may be slowing down or it may also suggest that there could be a rapid 
progression from the normal state through IGT to diabetes, which could imply a 
rapid increase in the diabetes epidemic or a worsening diabetogenic environment. 
In the Multicenter AIDS Cohort Study  in which the prevalence of diabetes 
and prediabetes was determined among the HIV seropositive persons and those 
receiving HAART. IN this study 1107  men were included and the prevalence of 
DM and prediabetes was determined at the index visit  . 
In our study only the HIV infected patients and the patients receiving 
HAART were included and they were divided into 5 groups. Comparison was 
made between these groups. In the Multicenter AIDS Cohort Study along with 
HIV infected patients and the patients receiving HAART, HIV seronegative 
participants also were included. 
In our study,out of 128 patients 100 patients were on HAART. 28 patients 
were not on any drugs. In the Multicenter AIDS Cohort Study 563 were HIV 
seronegative , 121 were HIV infected but not on any drugs and 423 were on 
HAART. 
In our study both males and females were included. Out of 128 patients 
60.2%were males and 39.8% were females. In the Multicenter AIDS Cohort Study 
all the participants were males. 
In  our study both fasting and postprandial blood glucose were taken for 
two consecutive days to find out the glucose intolerance.. In the Multicenter AIDS 
Cohort Study only single fasting glucose value was taken to define. glucose 
intolerance. 
The other two criterias to define the glucose intolerance were same in both 
our study and in the Multicenter AIDS Cohort Study i.e, use of anti-diabetic 
medication and self-reported diagnosis of DM. 
In our study patients did not receive protease inhibitors. In the Multicenter 
AIDS Cohort Study  protease inhibitors were  used in HAART. 
In the Multicenter AIDS Cohort Study  the prevalence of diabetes mellitus 
was  14%  in HIV positive group on HAART , 11% in HIV positive group not  on 
HAART and the prevalence of  DM was 5% in the HIV seronegative group. In our 
study also the prevalence of diabetes mellitus was  14%  in HIV positive group on 
HAART, 10.7% in HIV positive group not  on HAART .The overall prevalence of 
diabetes mellitus was 13.3 % . 
In comparing HIV seropositive patients on HAART with HIV seropositive 
not on any drugs , the prevalence of diabetes was significantly higher among 
patients on HAART . Considering individual groups ,patients in group 1 & 2 i.e, 
those on Stavudine+Lamivudine+Nevirapine & Stavudine + Lamivudine + 
Efavirenz  had higher prevalence with significant ‘p’ value. 
 
 
 
 
 
 
 
 
 
 
                                       SUMMARY 
 The study “PREVALENCE OF DIABETES IN HIV INFECTED 
PATIENTS AND HIV PATIENTS RECEIVING ANTIRETROVIRAL 
THERAPY” Was done in 128  patients  who were attending the anti retroviral 
therapy centre. GRH, Madurai .selected patients were divided into 5 Groups based 
on treatment they have received. Most of the patients were males. Patients on 
Stavudine+Lamivudine+Nevirapine were included in Group1, patients on 
Stavudine+Lamivudine +Efavirenz were included in Group2, Patients on 
Zidovudine+ Lamivudine +Nevirapine were included in Group 3, Patients on 
Zidovudine+ Lamivudine +Efavirenz were included in Group 4, and Patients not 
on any drugs were included in Group 5. 
Urine analysis, Fasting blood sugar after atleast 8 hours fasting , Post 
prandial blood sugar 2 hours after meal , Blood urea, S.creatinine , CD4 count, 
Liver function test, ECG were done for all the patients. 
Those patients with abnormal glucose value , the Fasting blood sugar and 
Post prandial blood sugar were repeated on the next day. 
Out of 128 patients,  2.3% of patients belong to < 10 years of age, 1.6% of 
patients belong to 10-19years of age, 26.6% of patients belong to 20-29 years of 
age, 43.8 % of patients belong to 30-39 years of age, 26% of patients  belong to 
40-49 years of age and 7% of patients  belong to 50 & Above years of age.    
60.2%were males and 39.8% were females. 
 10.8% had BMI of < 18.5 , 84.7% had BMI of 18.5 – 24.9 and 5% had 
BMI of > 24.9. All the 17 diabetic cases were within the range of 18.5 – 24.9. In   
IGT/IFG patients 90% were within the range of 18.5 – 24.9 and 10% were BMI of 
< 18.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     CONCLUSION  
 
1. Prevalence of diabetes mellitus was 14%  in HIV positive group on HAART,  
10.7% in HIV positive group not  on HAART. The overall prevalence of diabetes 
mellitus was 13.3 % in HIV patients. 
2. Prevalence of IGT/IFG was 8% in HIV positive group on HAART, 7.1% in 
HIV positive group not on HAART .The overall prevalence was 7.8 % in HIV 
patients. 
3. The prevalence of diabetes in HIV patients in our study was comparable to 
general population.  
4. The prevalence of diabetes was significantly higher in HIV patients receiving 
HAART than HIV patients not on HAART. 
5.Among HAART received  patients ,those on Stavudine+Lamivudine+Nevirapine 
& Stavudine+Lamivudine +Efavirenz  showed higher prevalence with significant 
‘p’ value.  
6. Among HAART drugs, protease inhibitors are well known to produce 
hyperglycemia.  In our study those on Stavudine + Lamivudine+Nevirapine & 
Stavudine+Lamivudine +Efavirenz also showed higher prevalence of Diabetes. 
7. So HIV patients on HAART should be periodically checked for blood glucose 
level. 
8. The prevalence of IGT/IFG in HIV patients was slightly lower than the general 
population. 
 Limitations: In our study only small number of [128] patients were 
involved and since it was a prevalence study the causal relationship was not able 
to obtained. It needs longitudinal study. 
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                                GLOSSARY 
AIDS                        -Acquired Immuno Deficiency Syndrome 
BMI                          - Body Mass index 
DM   - Diabetes Mellitus 
D4T(30)                          - Stavudine 
EFV                                 - Efavirenz 
GRH    - Government Rajaji Hospital 
HT    - Hypertension 
HAART                     -Highly Active Anti Retroviral Therapy 
IGT                             -Impaired Glucose tolerance 
IFG                             -Impaired Fasting Glucose 
NVP                                -  Nevirapine 
3TC                                 -  Lamivudine 
ZDV                                -  Zidovudine 
 
 
                                            
 
 
 
 
                                 PROFORMA 
Name:                                                              Age:                      Sex :                                                
 
IP/OP  No :                                                      Occupation : 
 
Marital status:                                                  WHO stage : 
 
Educational status : 
 
Clinical status : 
                  
           Polyuria  :    Y/N 
 
           Polydipsia :   Y /N 
 
           Polyphagia:   Y/N 
 
           Pruritus     :    Y/N 
 
Past History : 
 
           Diabetes :                               Hypertension : 
 
           IHD : 
 
 
Drug History :   Y/N               Allopathic/ Ayurvedic / Others  ( For HIV ) 
 
                                                 Anti Diabetic Agents 
                                                                                                         
 
Personal History :  
 
            Smoking:    Y/N            Duration:                      Packs/ Day 
 
            Alcohol   :    Y/N          Duration: 
 
             Diet        :    Veg/ Non veg 
 
 
 
 
 
Family History ; 
 
             Diabetes :     Y/N 
 
                       Father / Grand parents / Brother / Son  
 
                       Mother / Sister / Daughter  
 
Examination :                                                                  
 
        Height               Weight                        BMI     
 
Vital signs 
 
         (a) Pulse rate                                      (b) Respiratory rate 
  
         (c) Blood pressure 
 
 
Systems : 
 
Cardio vascular status                        
 
Respiratory status 
 
Neurological status                             
 
Treatment ; 
                         
                         1 . Lamivudine / Stavudine / Nevirapine 
 
                         2 . Lamivudine / Stavudine / Efavirenz  
 
                         3. Lamivudine / Zidovudine / Nevirapine 
 
                         4 . Lamivudine / Zidovudine / Efavirenz 
 
                         5. Not on drugs 
  
          
 
 
Investigations:  
 
Urine  albumin   : 
 
                Sugar      : 
 
               Deposit   :  
 
Blood sugar       :  
 
 
day 
 
Fasting [mg] 
 
Postprandial [mg] 
 
      1 
  
 
      2 
  
 
 Blood Urea       : 
  
Ser Creatinine   : 
 
Lipid profile      : 
 
 
Liver Function Test 
 
 
CD4  Count / ul   : 
 
      Percentage     :     
 
E.C.G.             
 
 
Ophthal evaluation : 
 
 
 
 
 
 
                                      MASTER CHART 
 
 
SN age sex M HT WT BMI S HTN G DM IGT/IFG N CAD 
1 33 F 1 16O 41 16 2 2 2 2 2 2 2 
2 35 F 1 160 43 17 2 2 2 2 2 2 2 
3 30 F 1 166 48 17 2 2 1 2 2 2 2 
4 50 M 1 163 47 18 1 1 1 2 2 2 2 
5 24 F 2 168 50 18 2 2 1 2 2 2 2 
6 29 F 1 156 43 18 2 2 3 2 2 2 2 
7 42 F 1 159 45 18 2 2 1 2 2 2 2 
8 29 F 1 160 46 18 2 2 3 2 2 2 2 
9 32 F 1 156 44 18 2 2 2 2 2 2 2 
10 45 M 1 163 48 18 2 2 2 2 2 2 2 
11 40 M 1 166 50 18 2 1 5 2 1 1 2 
12 33 M 1 169 52 18 2 2 5 2 2 2 2 
13 29 F 1 161 48 19 2 2 1 2 2 2 2 
14 26 F 1 161 48 19 2 2 1 2 2 2 2 
15 28 F 1 165 51 19 2 2 1 1 2 2 2 
16 31 F 1 163 50 19 2 1 2 2 1 1 2 
17 37 F 1 161 49 19 2 2 1 2 1 2 2 
18 43 M 1 170 55 19 2 2 2 2 2 2 2 
19 48 M 1 167 53 19 2 1 2 1 2 1 1 
20 35 F 1 162 50 19 2 2 1 2 2 2 2 
21 39 M 1 168 54 19 2 2 2 2 2 2 2 
22 33 M 1 168 54 19 2 2 2 2 2 2 2 
23 35 F 1 163 51 19 2 2 1 2 2 2 2 
24 42 M 1 174 58 19 2 2 1 1 2 2 2 
25 33 F 1 154 46 19 2 2 1 2 2 2 2 
26 35 F 1 159 49 19 2 2 2 1 2 2 2 
27 37 F 1 157 48 20 2 2 3 2 2 2 2 
28 32 M 1 169 56 20 2 2 1 2 2 2 2 
29 25 M 2 169 56 20 1 2 1 2 2 2 2 
30 25 M 1 173 59 20 2 2 1 2 2 2 2 
31 15 F 2 167 55 20 2 2 5 2 2 2 2 
32 35 M 2 168 56 20 2 2 3 2 2 2 2 
33 25 F 2 160 51 20 2 2 1 2 2 2 2 
34 4 M 2 88 16 21 2 2 4 1 2 2 2 
35 9 M 1 116 28 21 2 2 2 2 2 2 2 
36 22 F 1 153 47 20 2 2 1 2 2 2 2 
37 40 F 1 164 54 20 2 2 5 2 1 2 1 
38 31 F 1 168 57 20 2 2 5 2 2 2 2 
39 32 M 1 168 57 20 2 2 5 2 2 2 2 
40 30 M 1 167 57 20 2 2 1 2 2 2 2 
41 25 F 2 158 51 20 2 2 1 2 2 2 2 
42 35 F 1 158 51 20 2 2 3 1 2 2 2 
43 42 M 1 171 60 21 2 2 2 2 1 2 2 
44 28 M 1 168 58 21 1 2 2 2 2 2 2 
45 47 M 1 172 61 21 2 2 1 2 2 2 2 
46 50 M 1 160 53 21 2 1 1 2 1 2 1 
47 35 M 2 169 59 21 2 2 2 2 2 2 2 
48 42 M 1 166 57 21 1 2 3 2 2 2 2 
49 26 M 2 163 55 21 1 2 5 2 2 2 2 
50 38 F 1 164 56 21 2 1 1 1 2 1 1 
51 36 M 1 170 60 21 2 2 1 2 2 2 2 
52 30 M 1 170 60 21 2 2 3 2 2 2 2 
53 26 F 2 164 56 21 2 2 5 2 2 2 2 
54 29 F 1 170 60 21 2 2 4 2 2 2 2 
55 42 M 1 170 60 21 1 2 5 1 2 2 2 
56 36 M 1 168 59 21 2 2 1 2 1 2 2 
57 32 M 1 168 59 21 2 1 1 2 2 1 2 
58 23 F 1 166 58 21 2 2 5 2 2 2 2 
59 4 M 1 82 13 19 2 2 1 2 2 2 2 
60 36 M 1 166 58 21 2 2 5 2 2 2 2 
61 31 M 1 170 61 21 1 2 2 2 2 2 2 
62 28 M 1 160 54 21 2 2 5 2 2 2 2 
63 32 M 1 171 62 21 1 2 1 2 2 2 2 
64 44 M 1 164 57 21 2 2 5 2 2 2 2 
65 50 M 1 171 62 21 2 2 1 2 2 1 2 
66 29 M 1 167 59 21 2 2 1 2 2 2 2 
67 40 M 1 167 59 21 2 2 3 1 2 2 2 
68 27 F 1 161 55 21 2 2 2 2 2 2 2 
69 47 M 1 168 60 21 1 2 1 1 2 2 2 
70 37 F 1 165 58 21 2 2 4 2 1 2 2 
71 30 M 1 169 61 21 1 2 1 2 2 2 2 
72 45 M 1 169 61 21 2 2 1 2 2 2 2 
73 34 M 1 169 61 21 2 2 4 2 2 2 2 
74 44 M 1 169 61 21 2 1 5 1 2 1 1 
75 35 M 1 174 65 22 2 1 2 1 2 1 1 
76 51 F 1 160 55 22 2 2 2 1 2 2 2 
77 46 M 1 170 62 22 2 2 2 2 2 2 2 
78 35 F 1 167 60 22 2 2 5 2 2 2 2 
79 42 M 1 171 63 22 2 2 2 2 2 2 2 
80 34 M 1 158 54 22 2 2 1 2 2 2 2 
81 22 F 2 158 54 22 2 2 3 2 2 2 2 
82 40 M 1 169 62 22 1 1 1 1 2 1 1 
83 31 M 1 165 59 22 2 2 2 2 2 2 2 
84 35 M 1 169 62 22 2 2 1 2 2 2 2 
85 32 M 1 169 62 22 1 2 3 2 2 2 2 
86 35 F 1 163 58 22 2 2 5 2 2 2 2 
87 47 M 1 166 60 22 2 2 4 2 2 2 2 
88 45 M 1 166 60 22 2 1 4 2 2 2 2 
89 31 F 1 166 60 22 2 2 4 2 2 2 2 
90 19 F 2 167 61 22 2 2 5 2 2 2 2 
91 32 F 1 171 64 22 2 2 4 2 2 2 2 
92 50 M 1 165 60 22 1 1 5 2 2 2 1 
93 26 F 2 165 60 22 2 2 1 2 2 2 2 
94 57 M 1 165 60 22 2 2 5 2 2 2 2 
95 27 M 1 168 62 22 2 2 3 2 2 2 2 
96 30 M 1 168 62 22 2 2 3 2 2 2 2 
97 25 F 2 152 51 22 2 2 1 2 2 2 2 
98 30 F 1 166 61 22 2 2 5 2 2 2 2 
99 40 M 1 170 64 22 2 1 1 1 2 2 2 
100 32 M 1 170 64 22 2 2 2 2 2 2 2 
101 39 M 1 171 65 22 2 2 3 2 2 2 2 
102 38 M 1 168 63 22 1 1 5 2 2 2 2 
103 27 M 2 164 60 22 1 2 5 2 2 2 2 
104 35 M 1 168 63 22 2 2 1 2 2 2 2 
105 28 M 2 160 57 22 2 2 5 2 2 2 2 
106 40 M 1 165 61 22 2 1 1 2 1 2 2 
107 32 M 1 165 61 22 1 2 1 2 2 2 2 
108 36 F 1 161 58 22 2 2 3 2 2 2 2 
109 33 M 1 172 67 23 2 2 3 2 2 2 2 
110 29 F 1 165 62 23 2 2 1 2 2 2 2 
111 25 M 2 170 66 23 2 2 2 2 2 2 2 
112 47 M 1 170 66 23 2 2 1 2 2 2 2 
113 66 M 1 171 67 23 2 1 1 2 2 2 2 
114 37 M 1 171 67 23 1 2 1 1 2 2 2 
### 35 F 1 160 59 23 2 2 5 1 2 2 2 
116 26 M 2 158 58 23 2 2 5 2 2 2 2 
117 36 F 1 162 61 23 2 2 1 2 2 2 2 
118 35 M 1 176 72 23 1 2 3 2 2 2 2 
119 27 M 2 171 68 23 2 2 1 2 2 2 2 
120 24 F 2 168 66 23 2 2 1 2 2 2 2 
121 40 M 1 157 60 24 1 2 5 2 2 2 2 
122 28 M 1 159 63 25 2 2 3 2 1 2 2 
123 23 F 2 158 64 26 2 2 2 2 2 2 2 
124 28 F 1 161 67 26 2 2 1 2 2 2 2 
125 36 F 1 160 66 26 2 2 3 2 2 2 2 
126 33 M 1 158 65 26 1 2 5 2 2 2 2 
127 27 F 2 160 68 27 2 2 1 2 2 2 2 
128 46 F 1 166 60 22 2 2 5 2 2 2 2 
              
 
 
 
 
 
 
 
 
 
 
 
 
Sex:     M-Male, F-Female                    M-Marital status  : 1-married , 2-Unmarried 
 
S – Smoking :   1 –Yes ,  2 – No           HT: 1-Present, 2-Absent                                       
G – Group :1,2,3,4&5                            DM:     1-Present, 2-Absent                                   
HT: 1-Present, 2-Absent                        IGT/IFG : 1-Present, 2-Absent                              
CAD:    1-Present, 2-Absent 
N – Nephropathy : 1-Present, 2-Absent 
 
 
